May 24, 2020
HistoIndex's AI-based Digital Pathology Platform: A Validated Quantification Tool Recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China
Mar 10, 2020
The global market for biopsy devices is predicted to exceed US$ 3 Billion by 2025
Feb 06, 2020
ProSciento and Nordic Bioscience Form Strategic Partnership to Develop Translational Biomarkers for Nonalcoholic Steatohepatitis (NASH)
Jan 13, 2020
Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients
Nov 09, 2019
qFIBS Demonstrates Suitability for Nonalcoholic Steatohepatitis (NASH) Assessment in Clinical Trials and Patient Care with Full Quantification of All Crucial Histopathological Features
Oct 30, 2019
PharmaNest Announces New Adult and Pediatric NASH Data to Be Presented at the AASLD - Liver Meeting® 2019
Sep 24, 2019
PharmaNest Launches FibroNest, the First Multivendor Image Analysis and Translational Platform for the Assessment of the Severity and Progression of Fibrosis in NASH
Dec 23, 2018
HistoIndex's Second Harmonic Generation (SHG) Technology: A Potentially Important Tool Used In Madrigal's Phase 2 Nonalcoholic Steatohepatitis (NASH) Clinical Trial
Nov 09, 2018
Predicting Clinical Outcomes With Multiparametric MRI Featuring Liver cT1 Equal to Biopsy, According to Research Presented at The Liver Meeting® 2018
Jun 07, 2018
A Worldwide Effort to Defeat Nonalcoholic Steatohepatitis (NASH)
May 02, 2018
Cirius Therapeutics Reaches Enrollment Target in Phase 2b EMMINENCE Trial in NASH
Oct 24, 2017
Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Oct 20, 2017
Confirmatory Results of the Second Phase 3 Lusutrombopag (S-888711) Study (L-PLUS 2) Presented at the 2017 Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD)
Oct 16, 2017
Noninvasive PROMETHEUS® FIBROSpect® NASH Test Measures Severity of Liver Fibrosis
Sep 25, 2017
Shionogi Announces Results for Lusutrombopag (S-888711) Phase 3 Study (L-PLUS2) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
Aug 18, 2017
NASH (Non-alcoholic Steatohepatitis) Biomarkers Market to Reach $2 Billion by 2025: Increasing Incidence of Chronic Liver Diseases is Expected to Propel Demand in this Market
Jun 06, 2017
Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)
May 31, 2017
All Heart Patients Have Some Liver Disease after Fontan Surgery